3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Carcinoma, Merkel Cell
8
Urinary Bladder Neoplasms
7
Pancreatic Neoplasms
6
Neoplasm Metastasis
6
Triple Negative Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Ovarian Neoplasms
4
Neoplasms
4
Stomach Neoplasms
3
Prostatic Neoplasms
3
Melanoma
3
Leukemia, Myeloid, Acute
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Sarcoma
2
Head and Neck Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Squamous Cell
2
Carcinoma, Ovarian Epithelial
2
Carcinoma
2
Uterine Cervical Neoplasms
1
Ureteral Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Recurrence
1
Ovarian Diseases
1
Non-Muscle Invasive Bladder Neoplasms
1
Neuroendocrine Tumors
1
Interventions
Etoposide
18
Carboplatin
18
pembrolizumab
15
Nivolumab
11
Cisplatin
11
atezolizumab
8
Topotecan
8
Irinotecan
7
Temozolomide
6
Paclitaxel
5
PM 01183
5
Ipilimumab
5
Gemcitabine
5
olaparib
4
Radiotherapy
4
Docetaxel
4
surufatinib
3
durvalumab
3
carfilzomib
3
Bevacizumab
3
veliparib
2
trilaciclib
2
sacituzumab govitecan
2
rovalpituzumab tesirine
2
obatoclax
2
niraparib
2
navitoclax
2
lorvotuzumab mertansine
2
lenvatinib
2
fluzoparib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Small Cell Lung Carcinoma
×
avelumab
×
Clear all
NCT02554812
2024-07-30
JAVELIN Medley
Pfizer
Phase 1/2
Terminated
409 enrolled
108 charts